| NCT03947255 |
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03947255 |
Recruiting |
Seattle Genetics, Inc. |
2024-12-31 |
| NCT03552692 |
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03552692 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2020-08-31 |
| NCT03372057 |
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03372057 |
Recruiting |
Verastem, Inc. |
2021-11-30 |
| NCT03321890 |
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03321890 |
Recruiting |
Sun Yat-sen University |
2020-12-01 |
| NCT03278782 |
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
https://ClinicalTrials.gov/show/NCT03278782 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03268889 |
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) |
https://ClinicalTrials.gov/show/NCT03268889 |
Recruiting |
The First Affiliated Hospital of Soochow University |
2020-06-15 |
| NCT03212937 |
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03212937 |
Active, not recruiting |
National Cancer Centre, Singapore |
2020-02-29 |
| NCT03210662 |
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03210662 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03150602 |
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy |
https://ClinicalTrials.gov/show/NCT03150602 |
Recruiting |
Taiwan Mundipharma Pharmaceuticals Ltd. |
2020-12-31 |
| NCT03141203 |
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03141203 |
Active, not recruiting |
University of Birmingham |
2020-08-31 |
| NCT03113500 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03113500 |
Recruiting |
City of Hope Medical Center |
2021-01-21 |
| NCT03071822 |
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03071822 |
Recruiting |
The University of Hong Kong |
2021-07-31 |
| NCT03046953 |
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03046953 |
Recruiting |
University of Birmingham |
2020-08-31 |
| NCT03017820 |
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03017820 |
Recruiting |
Mayo Clinic |
2021-01-15 |
| NCT03011814 |
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03011814 |
Recruiting |
City of Hope Medical Center |
2023-03-08 |
| NCT02987244 |
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02987244 |
Recruiting |
Peking Union Medical College Hospital |
2020-03-31 |
| NCT02978625 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
https://ClinicalTrials.gov/show/NCT02978625 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT02953652 |
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02953652 |
Active, not recruiting |
HUYA Bioscience International |
2019-04-30 |
| NCT02879526 |
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02879526 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2019-06-30 |
| NCT02809573 |
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02809573 |
Completed |
Chipscreen Biosciences, Ltd. |
2019-01-08 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02689453 |
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) |
https://ClinicalTrials.gov/show/NCT02689453 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-01-31 |
| NCT02676778 |
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02676778 |
Completed |
Eisai Inc. |
2019-04-24 |
| NCT02653976 |
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02653976 |
Active, not recruiting |
Solasia Pharma K.K. |
2019-12-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02594267 |
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02594267 |
Active, not recruiting |
Acrotech Biopharma LLC |
2020-08-31 |
| NCT02588651 |
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) |
https://ClinicalTrials.gov/show/NCT02588651 |
Recruiting |
Case Comprehensive Cancer Center |
2020-08-31 |
| NCT02576496 |
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02576496 |
Recruiting |
Mundipharma-EDO GmbH |
2021-03-31 |
| NCT01716806 |
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01716806 |
Recruiting |
Seattle Genetics, Inc. |
2021-09-30 |
| NCT01614197 |
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT01614197 |
Completed |
Therapeutic Advances in Childhood Leukemia Consortium |
2019-12-15 |
| NCT02567656 |
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02567656 |
Completed |
Rhizen Pharmaceuticals SA |
2018-03-31 |
| NCT02561273 |
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02561273 |
Active, not recruiting |
University of Nebraska |
2020-10-31 |
| NCT02535247 |
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02535247 |
Recruiting |
Fox Chase Cancer Center |
2020-12-31 |
| NCT02533700 |
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL |
https://ClinicalTrials.gov/show/NCT02533700 |
Active, not recruiting |
Shandong Provincial Hospital |
2019-05-31 |
| NCT02520791 |
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02520791 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02512497 |
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02512497 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-12-31 |
| NCT02495415 |
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02495415 |
Recruiting |
CerRx, Inc. |
2021-07-31 |
| NCT02464228 |
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. |
https://ClinicalTrials.gov/show/NCT02464228 |
Active, not recruiting |
Kura Oncology, Inc. |
2021-01-15 |
| NCT02445404 |
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL |
https://ClinicalTrials.gov/show/NCT02445404 |
Recruiting |
Samsung Medical Center |
2020-06-30 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02424045 |
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02424045 |
Completed |
Samsung Medical Center |
2017-09-30 |
| NCT02362997 |
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL |
https://ClinicalTrials.gov/show/NCT02362997 |
Recruiting |
Dana-Farber Cancer Institute |
2020-09-30 |
| NCT02342782 |
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02342782 |
Active, not recruiting |
City of Hope Medical Center |
2020-12-31 |
| NCT02264613 |
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT02264613 |
Active, not recruiting |
Aileron Therapeutics |
2020-03-31 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02232516 |
Recruiting |
Northwestern University |
2022-07-31 |
| NCT02223208 |
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02223208 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2021-09-30 |
| NCT02181218 |
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT02181218 |
Active, not recruiting |
Washington University School of Medicine |
2019-03-28 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT02158975 |
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02158975 |
Completed |
University of Michigan Rogel Cancer Center |
2016-10-31 |
| NCT02142530 |
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL |
https://ClinicalTrials.gov/show/NCT02142530 |
Completed |
Massachusetts General Hospital |
2017-03-31 |
| NCT02106650 |
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02106650 |
Completed |
Acrotech Biopharma LLC |
2018-10-31 |
| NCT01280526 |
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01280526 |
Completed |
The Lymphoma Academic Research Organisation |
2012-11-30 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT04018248 |
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) |
https://ClinicalTrials.gov/show/NCT04018248 |
Recruiting |
Boryung Pharmaceutical Co., Ltd |
2023-12-31 |
| NCT02013362 |
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02013362 |
Completed |
Mundipharma K.K. |
2015-12-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01846390 |
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01846390 |
Completed |
Canadian Cancer Trials Group |
2016-07-06 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01839097 |
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01839097 |
Completed |
Acrotech Biopharma LLC |
2016-01-31 |
| NCT01822886 |
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01822886 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2014-12-31 |
| NCT01806337 |
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01806337 |
Completed |
University of Göttingen |
2006-07-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01796002 |
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01796002 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2020-03-20 |
| NCT01787409 |
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
https://ClinicalTrials.gov/show/NCT01787409 |
Recruiting |
Mayo Clinic |
2020-11-30 |
| NCT01777152 |
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01777152 |
Active, not recruiting |
Seattle Genetics, Inc. |
2018-08-15 |
| NCT01776411 |
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01776411 |
Completed |
Mundipharma K.K. |
2016-03-31 |
| NCT01767766 |
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01767766 |
Completed |
TG Therapeutics, Inc. |
2018-02-28 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01719835 |
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study |
https://ClinicalTrials.gov/show/NCT01719835 |
Active, not recruiting |
Royal Marsden NHS Foundation Trust |
2016-11-30 |
| NCT01689220 |
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea |
https://ClinicalTrials.gov/show/NCT01689220 |
Completed |
Solasia Pharma K.K. |
2014-01-31 |
| NCT01679860 |
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01679860 |
Completed |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2011-12-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01664975 |
Treatment of Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01664975 |
Completed |
Zhengzhou University |
2016-04-30 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01644253 |
Phase 1b Safety and Efficacy Study of TRU-016 |
https://ClinicalTrials.gov/show/NCT01644253 |
Active, not recruiting |
Aptevo Therapeutics |
2020-10-31 |
| NCT01638533 |
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT01638533 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-11-29 |
| NCT01611142 |
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01611142 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2015-05-31 |
| NCT01590732 |
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01590732 |
Completed |
M.D. Anderson Cancer Center |
2018-05-02 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT03349333 |
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL |
https://ClinicalTrials.gov/show/NCT03349333 |
Completed |
Mundipharma (China) Pharmaceutical Co. Ltd |
2017-07-21 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01482962 |
Alisertib (MLN8237) or Investigator’s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01482962 |
Completed |
Takeda |
2015-06-30 |
| NCT01466881 |
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01466881 |
Completed |
National Cancer Institute (NCI) |
2014-12-31 |
| NCT01456039 |
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01456039 |
Completed |
Celgene |
2015-07-28 |
| NCT01435863 |
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01435863 |
Completed |
Solasia Pharma K.K. |
2015-04-30 |
| NCT01431209 |
Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01431209 |
Active, not recruiting |
University of Nebraska |
2021-03-31 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01403415 |
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01403415 |
Completed |
National Cancer Institute (NCI) |
2015-05-31 |
| NCT01336933 |
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01336933 |
Completed |
University of Nebraska |
2016-12-28 |
| NCT01336920 |
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01336920 |
Completed |
University of Nebraska |
2015-04-30 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04444141 |
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04444141 |
Recruiting |
Akeso |
2021-06-30 |
| NCT04423926 |
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL |
https://ClinicalTrials.gov/show/NCT04423926 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2022-12-31 |
| NCT04362007 |
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04362007 |
Recruiting |
Otsuka Pharmaceutical Co., Ltd. |
2024-09-30 |
| NCT04329130 |
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04329130 |
Recruiting |
Sun Yat-sen University |
2022-03-26 |
| NCT04254107 |
A Safety Study of SGN-TGT in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT04254107 |
Recruiting |
Seattle Genetics, Inc. |
2022-12-31 |
| NCT04105010 |
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) |
https://ClinicalTrials.gov/show/NCT04105010 |
Recruiting |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
2020-12-31 |
| NCT04101331 |
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT04101331 |
Recruiting |
Affimed GmbH |
2022-04-30 |
| NCT04083495 |
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04083495 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2021-09-30 |
| NCT04061772 |
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04061772 |
Recruiting |
Zhejiang Cancer Hospital |
2021-07-05 |
| NCT04045470 |
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04045470 |
Recruiting |
Dana-Farber Cancer Institute |
2023-01-01 |
| NCT04040491 |
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04040491 |
Recruiting |
Zhengzhou University |
2020-12-01 |
| NCT04028440 |
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL) |
https://ClinicalTrials.gov/show/NCT04028440 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2020-12-31 |
| NCT04008394 |
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies |
https://ClinicalTrials.gov/show/NCT04008394 |
Recruiting |
Wuhan Union Hospital, China |
2022-07-01 |
| NCT03952572 |
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03952572 |
Recruiting |
Peking University |
2023-04-30 |
| NCT03927105 |
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03927105 |
Active, not recruiting |
Big Ten Cancer Research Consortium |
2024-05-31 |
| NCT03921879 |
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT03921879 |
Recruiting |
Oncotartis, Inc. |
2021-04-30 |
| NCT03905135 |
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies |
https://ClinicalTrials.gov/show/NCT03905135 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-03-01 |
| NCT03902184 |
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03902184 |
Recruiting |
Innate Pharma |
2022-03-01 |
| NCT03776279 |
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03776279 |
Recruiting |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2020-12-30 |
| NCT03719105 |
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma |
https://ClinicalTrials.gov/show/NCT03719105 |
Recruiting |
New York Medical College |
2022-12-31 |
| NCT03631862 |
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03631862 |
Recruiting |
Zhengzhou University |
2019-12-31 |
| NCT03629873 |
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects |
https://ClinicalTrials.gov/show/NCT03629873 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2019-08-01 |
| NCT03617432 |
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03617432 |
Recruiting |
Peking University |
2020-09-30 |
| NCT03601819 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT03601819 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-09-30 |
| NCT03598998 |
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03598998 |
Recruiting |
City of Hope Medical Center |
2021-04-27 |
| NCT03590574 |
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03590574 |
Recruiting |
Autolus Limited |
2021-07-31 |
| NCT03586999 |
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03586999 |
Recruiting |
University of Colorado, Denver |
2020-08-31 |
| NCT03547700 |
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03547700 |
Recruiting |
Big Ten Cancer Research Consortium |
2020-07-31 |
| NCT03542266 |
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03542266 |
Active, not recruiting |
Weill Medical College of Cornell University |
2020-03-25 |
| NCT03534180 |
Venetoclax in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03534180 |
Recruiting |
City of Hope Medical Center |
2020-08-21 |
| NCT03502629 |
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) |
https://ClinicalTrials.gov/show/NCT03502629 |
Recruiting |
Genor Biopharma Co., Ltd. |
2020-08-31 |
| NCT03501576 |
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT03501576 |
Recruiting |
Emory University |
2021-04-30 |
| NCT03496779 |
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine |
https://ClinicalTrials.gov/show/NCT03496779 |
Recruiting |
The Lymphoma Academic Research Organisation |
2020-03-31 |
| NCT03493451 |
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms |
https://ClinicalTrials.gov/show/NCT03493451 |
Active, not recruiting |
BeiGene |
2021-02-28 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01226472 |
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 |
https://ClinicalTrials.gov/show/NCT01226472 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2012-09-30 |
| NCT01198665 |
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01198665 |
Completed |
Samsung Medical Center |
2014-12-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01169298 |
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01169298 |
Completed |
Celgene |
2013-12-01 |
| NCT01155817 |
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01155817 |
Completed |
Stanford University |
2013-12-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01129180 |
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01129180 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT00970385 |
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00970385 |
Completed |
University Hospital, Grenoble |
2002-12-31 |
| NCT00930605 |
The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT00930605 |
Completed |
King Chulalongkorn Memorial Hospital |
2006-11-30 |
| NCT00901147 |
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00901147 |
Completed |
Singapore General Hospital |
2014-01-31 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00888927 |
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00888927 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2012-09-30 |
| NCT00865969 |
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00865969 |
Completed |
Spectrum Pharmaceuticals, Inc |
2014-10-31 |
| NCT03922724 |
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03922724 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-05-27 |
| NCT01401530 |
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01401530 |
Completed |
Eisai Inc. |
2015-08-31 |
| NCT00791947 |
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT |
https://ClinicalTrials.gov/show/NCT00791947 |
Completed |
University of Aarhus |
2008-08-31 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00646854 |
Alemtuzumab and CHOP in T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00646854 |
Completed |
University of Aarhus |
2016-12-31 |
| NCT00644189 |
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00644189 |
Active, not recruiting |
Massachusetts General Hospital |
2013-12-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00571662 |
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00571662 |
Completed |
University of Nebraska |
2008-12-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00481871 |
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
https://ClinicalTrials.gov/show/NCT00481871 |
Completed |
Acrotech Biopharma LLC |
2011-05-31 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00453427 |
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00453427 |
Completed |
Ontario Clinical Oncology Group (OCOG) |
2013-06-30 |
| NCT00426764 |
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00426764 |
Completed |
Celgene |
2010-11-11 |
| NCT00406809 |
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00406809 |
Completed |
AbbVie |
2016-10-31 |
| NCT00374699 |
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00374699 |
Completed |
Samsung Medical Center |
2009-09-30 |
| NCT00364923 |
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00364923 |
Completed |
Acrotech Biopharma LLC |
2009-01-31 |
| NCT00355472 |
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL |
https://ClinicalTrials.gov/show/NCT00355472 |
Completed |
Kyowa Kirin Co., Ltd. |
2008-10-31 |
| NCT00337987 |
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00337987 |
Completed |
Yale University |
2007-12-31 |
| NCT00290433 |
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00290433 |
Completed |
M.D. Anderson Cancer Center |
2015-07-31 |
| NCT00211185 |
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00211185 |
Completed |
Eisai Inc. |
2008-08-31 |
| NCT00136565 |
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00136565 |
Completed |
Lymphoma Study Association |
2011-04-18 |
| NCT00131937 |
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00131937 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00038025 |
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00038025 |
Completed |
M.D. Anderson Cancer Center |
2006-11-29 |
| NCT00007345 |
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00007345 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-01-26 |